Visram, A. http://orcid.org/0000-0002-7201-4642
De La Torre, A.
White, D.
Su, J.
Masih-Khan, E.
Chu, M.
Jimenez-Zepeda, V.
McCurdy, A. http://orcid.org/0000-0002-8809-4368
LeBlanc, R.
Song, K.
Mian, H. http://orcid.org/0000-0003-1584-1067
Louzada, M.
Sebag, M.
Bergstrom, D.
Stakiw, J.
Reiman, A.
Kotb, R.
Aslam, M.
Venner, C.
Kaedbey, R.
Gul, E. http://orcid.org/0000-0002-3922-3215
Reece, D.
Article History
Received: 18 June 2023
Revised: 9 October 2023
Accepted: 7 November 2023
First Online: 8 December 2023
Competing interests
: AV: Consultancy/Honoraria fees from Janssen, Sanofi, Pfizer. HM: Consultancy/Honoraria fees from Celgene/BMS, Takeda, Janssen, Amgen, Sanofi, Pfizer, GSK; Research funding Janssen. RL: Consultancy/Honoraria fees from Janssen, BMS, Amgen, Sanofi, Forus Therapeutics. CPV: Honoraria from Janssen, BMS, Sanofi, Pfizer, Amgen, BMS/Celgene, Takeda, Forus. VJZ Honoraria Janssen, BMS, Sanofi, Pfizer, Amgen, BMS/Celgene, Takeda and Forus Therapeutics. TR: consultancy/honoraria from Janssen, Pfizer, Sanofi, Celgene/BMS, Takeda, Amgen.